Gilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction valued at up to $5bn.

The tender offer is for €51.29 per share, representing a 13% premium on Recordati’s share price before the takeover was first disclosed.

Cases of syphilis and gonorrhoea have tripled and quadrupled, respectively, since 2015, highlighting the need for effective treatments.

Concept Life Sciences has signed a strategic partnership with OpenBench to deliver success-based drug discovery services targeted at early-stage biotech companies.

Regeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on AHCs.

The new healthcare firm will operate across the North American, APAC and European markets, which make up around 90% of the global R&D spend.

Eli Lilly has acquired Engage Bio and its preclinical, non-viral DNA delivery platform. Credit: Tada Images / Shutterstock.com. Pharmaceutical giant Eli Lilly has agreed to acquire Engage Biologics ...

QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery.

Gilead will donate vials of its antifungal medication AmBisome to help global efforts in eliminating visceral leishmaniasis.

Bristol Myers Squibb (BMS) has signed a strategic agreement with Anthropic to implement its Claude platform across its global operations.

SERB Pharmaceuticals has signed an agreement to acquire exclusive development and commercialisation rights to Idefirix from Hansa Biopharma for a total of $133.6m.

The healthcare team covers Q1 results from pharma and medtech companies and provides a wrap-up of the key takeaways ...